Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The term "tumor cell (via preserved anti-tumor cytotoxicity)" refers to targeting tumor cells by maintaining or enhancing the cytotoxic functions of immune effector cells (T lymphocytes and NK cells) capable of recognizing and killing cancer cells. This approach is central to many immunotherapies, which aim to preserve or boost the body's natural ability to eliminate tumor cells. Key strategies involve blocking inhibitory checkpoint receptors, enhancing co-stimulatory signals, or adoptive transfer of engineered immune cells with preserved cytolytic function.
Enhancement or preservation of cytotoxic T lymphocyte (CTL) and NK cell-mediated killing of tumor cells, often through blockade of inhibitory checkpoints or adoptive transfer of engineered immune cells.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor cell (via preserved anti-tumor cytotoxicity).